IGSF8 靶点蛋白|抗体药物|临床药物信息 - ACROBiosystems中国

> 【IGSF8】

IGSF8信息

英文名称：Immunoglobulin superfamily member 8
中文名称：免疫球蛋白超家族成员 8
靶点别称：IgSF8，CD81 partner 3，Glu-Trp-Ile EWI motif-containing protein 2，EWI-2，Keratinocytes-associated transmembrane protein 4，KCT-4，LIR-D1，Prostaglandin regulatory-like protein，PGRL，CD316，CD81P3，EWI2，KCT4

上市药物数量：0
临床药物数量：1
最高研发阶段：临床二期

IGSF8产品列表

筛选结果

产品库

在线 (1)

物种

Human (1)

标签

His Tag & Avi Tag (1)

属性

Protein (1)

标记

Biotin-labeled (1)

货号	物种	产品描述	蛋白结构	纯度	活性
IG8-H82Q3	Human	Biotinylated Human IGSF8 Protein, Avitag™,His Tag (MALS verified)

ACRO质量管理体系

评论(0)

IGSF8分子别名

IgSF8,CD316,CD81P3,EWI-2,EWI2,KCT-4,LIR-D1,PGRL

IGSF8分子背景

IGSF8 (Immunoglobulin superfamily member 8) is a member the EWI subfamily of the immunoglobulin protein superfamily, also known as EWI-2, KCT-4, LIR-D1, and PGRL. It interacts with the tetraspanins CD81 and CD9 and may regulate their role in certain cellular functions including cell migration and viral infection. IGSF8 suppresses T-cell mobility coordinately with CD81, associates with CD82 to suppress prostate cancer cell migration, regulates epidermoid cell reaggregation and motility on laminin-5 with CD9 and CD81 as key linkers. It may also play a role on integrin-dependent morphology and motility functions, and may participate in the regulation of neurite outgrowth and maintenance of the neural network in the adult brain. Recent research indicates that IGSF8 is highly expressed on malignant cells with antigen presentation defects, and it interacts with NK receptors to suppress NK cell cytotoxicity.

IGSF8临床药物信息

英文名称	研发代码	研发阶段	公司	适应症	临床试验
GV20-0251	GV200251; XBH 25; XBH-25; GV20-0251; XBH25; GV20 0251	临床二期	上海寻百会生物科技有限公司	实体瘤, 皮肤黑色素瘤, 肿瘤, 结直肠癌, 子宫内膜癌, 非小细胞肺癌	详情

扫一扫关注微信公众号获取ACRO最新资讯

ACROBiosystems百普赛斯生物科技股份有限公司

全国：+86 400-682-2521

北京：010-53681107

上海：021-50850665

海外：+1 800-810-0816

邮箱：（产品订购）order.cn@acrobiosystems.com

邮箱：（技术支持）tech.cn@acrobiosystems.com

邮箱：（廉洁合规）lianjie@acrobiosystems.com

地址：北京经济技术开发区宏达北路8号5号楼4层

在线留言

发送

消息提示

请输入您的联系方式,再点击提交！